Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...

New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.

With this information in hand, researchers who are developing a gene therapy to treat a muscle condition, for instance, could use the atlas to identify AAV vectors that preferentially target the ...

Viral vectors introduce genes and gene editing sequences into cells, and are a popular platform for gene therapy due to their safety and efficacy features. Adeno-associated viral (AAV) vectors in ...

DELRAY BEACH, FL / ACCESS Newswire / August 12, 2025 / Adolore BioTherapeutics, Inc., (“Company” or “Adolore”) announced that Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, ...

Duchenne muscular dystrophy is the most common early onset form of muscular dystrophy; many boys become wheelchair bound in their teens and die in their twenties. People with limb girdle muscular ...

Learn about comparative gene expression studies in Alzheimer's disease and other conditions in Mayo Clinic's Precision Medicine in Neurodegeneration Lab.